Risperidone in the treatment of schizophrenia: A meta-analysis of randomized controlled trials

Journal of Psychopharmacology

Volumn 11, Issue 1, 1997, Pages 65-71

  Song, Fujian ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

Author keywords

Meta analysis; Risperidone; Schizophrenia

Indexed keywords

HALOPERIDOL; NEUROLEPTIC AGENT; RISPERIDONE;

ASTHENIA; BODY WEIGHT DISORDER; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG USE; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FEMALE; HEADACHE; HEART PALPITATION; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MALE SEXUAL DYSFUNCTION; META ANALYSIS; NAUSEA; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHINITIS; SCHIZOPHRENIA; TACHYCARDIA; VOMITING; WEIGHT GAIN;

BASAL GANGLIA DISEASES; HUMANS; PSYCHIATRIC STATUS RATING SCALES; RISPERIDONE; SCHIZOPHRENIA;

EID: 0030975653     PISSN: 02698811     EISSN: None     Source Type: Journal    
DOI: 10.1177/026988119701100116     Document Type: Review

References (39)

1. Andreasen N C (1985) Positive vs negative schizophrenia: a critical evaluation. Schizophren Bull 11: 380-389
2. Bailey K R (1994) Generalizing the results of randomized clinical trials. Control Clin Trials 15: 15-23
3. Blin O, Azorin J M, Bouhours P (1995) Antipsychotic and anxiolytic properties of risperidone, haloperidol and methotrimeprazin in schizophrenic patients. [unpublished data from Janssen]
4. Borison R et al. (1991) Risperidone versus haloperidol versus placebo in the treatment of schizophrenia. Clinical Research Report (RIS-USA-9001, N83170) [unpublished data from Janssen]
5. Borison R L, Pathiraja A P, Diamond B I, Meibach R C (1992) Risperidone: clinical safety and efficacy in schizophrenia. Psychopharmocology 28: 213-218
6. Cardoni A A (1995) Risperidone: review and assessment of its role in the treatment of schizophrenia. Ann Pharmacotherap 29: 610-618
7. Carpenter W T, Buchanan R W (1994) Schizophrenia. N Engl J Med 330: 681-690
8. Ceskova E, Svestka J (1993) Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses. Pharmacopsychiatry 26: 121-124
9. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan G W et al. (1993) A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmac 13: 25-40
10. Christison G W, Kirch D G, Wyatt R J (1991) When symptoms persist: choosing among alternative somatic treatments for schizophrenia. Schizophren Bull 17: 217-245
11. Claus A, Bollen J, De Cuyper H, Eneman M, Malfroid M, Peuskens J et al. (1992) Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta Psychiat Scand 85: 295-305
12. Curtis V A, Kerwin R W (1995) A risk-benefit assessment of risperidone in schizophrenia. Drug Safety 12: 139-145
13. Davis J M, Casper R (1977) Antipsychotic drugs: clinical pharmacology and therapeutic use. Drugs 14: 260-282
14. Edwards J G (1994) Risperidone for schizophrenia: encouraging results awaiting further research. BMJ 308: 1311-1312
15. Emerson J D (1994) Combining estimates of the odds ratio: the state of the art. Stat Methods Med Res 3: 157-178
16. Gitlin M J, Midha K K, Fogelson D, Nuechterlein K (1988) Persistence of fluphenazine in plasma after decanoate withdrawal. J Clin Psychopharmac 8: 53-56
17. Heinrich K, Klieser E, Lehmann E, Kinzler E, Hruschka H (1994) Risperidone versus clozapine in the treatment of schizophrenic patients with acute symptoms: a double-blind, randomized trial. Prog Neuro-Psychopharmac Biol Psychiat 18: 129-137
18. Hoyberg O J, Fensbo C, Remvig J, Lingjaerde O, Sloth-Nielsen M, Salvesen I (1993) Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. Acta Psychiat Scand 88: 395-402
19. Huttunen M, Piepponen T, Rantanen H, Larmo I, Nyholm R, Raitasuo V (1995) Risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes: a double-blind parallel-group trial. Acta Psychiat Scand 91: 271-277
20. Johnson A L, Johnson A W (1995) Peer review of 'Risperidone in the treatment of patients with chronic schizophrenia: a multinational, multi-centre, double-blind, parallel-group study versus haloperidol'. Br J Psychiat 166: 727-733
21. Kane JM (1996) Schizophrenia. New Engl J Med 334: 34-41
22. Kane J M, Marder S R (1993) Psychopharmacologic treatment of schizophrenia. Schizophren Bull 19: 287-302
23. Kay S R, Fiszbein A, Opler L A (1987) The Positive and Negative Syndrome Scale (PANS) for schizophrenia. Schizophren Bull 13: 261-267
24. Kerwin R W (1994) The new atypical antipsychotics: a lack of extrapyramidal side-effects and new routes in schizophrenia research. Br J Psychiat 164: 141-148
25. Livingston M G (1994) Risperidone. Lancet 343: 457-460
26. McEvoy J P, Hogarty G E, Steingard S (1991) Optimal dose of neuroleptic in acute schizophrenia: a controlled study of the neuroleptic threshold and higher haloperidol dose. Arch Gen Psychiat 45: 739-745
27. Marder S R, Meibach R C (1994) Risperidone in the treatment of schizophrenia. Am J Psychiat 151: 825-835
28. Mesotten F et al. (1991) Risperidone versus haloperidol in the treatment of chronic psychotic patients: a multicentre double-blind study. Clinical Research Report (RIS-INT-2, N 85163) [unpublished data from Janssen]
29. Min S K, Rhee C S, Kim C E, Kang D Y (1993) Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: a parallel group double-blind comparative trial. Yansei Med J 34: 179-190
30. Moller H J et al. (Working Group on Negative Symptoms in Schizophrenia) (1994) Negative symptoms in schizophrenia: considerations for clinical trials. Psychopharmacology 115: 221-228
31. Overall J E, Gorham D R (1988) Introduction - The Brief Psychiatric Rating Scale (BPRS): recent developments in ascertainment and scaling. Psychopharmac Bull 24: 97-99
32. Peuskens J et al. (The Risperidone Study Group) (1995) Risperidone in the treatment of chronic schizophrenic patients: an international multicentre double-blind parallel-group comparative study versus haloperidol. Br J Psychiat 166: 712-726
33. Ray W A, Griffin M R, Avorn J (1993) Evaluating drugs after their approval for clinical use. N Engl J Med 329: 2029-2032
34. Thompson S G (1994) Why sources of heterogeneity in meta-analysis should be investigated. BMJ 309: 1351-1355
35. Thompson S G, Pocock S J (1991) Can meta-analyses be trusted? Lancet 338: 1127-1130
36. Umbricht D, Kane J M (1995) Risperidone: efficacy and safety. Schizophren Bull 21: 593-606
37. Van Putten T, Marder S R (1987) Behavioral toxicity of antipsychotic drugs. J Clin Psychiat 48(Suppl. 9): 13-19
38. Van Putten T, Marder S R, Mintz J, Poland R E (1992) Haloperidol plasma levels and clinical response: a therapeutic window relationship. Am J Psychiat 149: 500-505
39. Whitehead A, Whitehead J (1991) A general parametric approach to the meta-analysis of randomized clinical trials. Stat Med 10: 1665-1677